You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy
|
|---|---|
| Published in |
Frontiers in oncology, February 2021
|
| DOI | 10.3389/fonc.2021.621992 |
| Pubmed ID | |
| Authors |
Yulong Fu, Anqi Wang, Jieqi Zhou, Wei Feng, Minhua Shi, Xiao Xu, Hongqing Zhao, Liming Cai, Jian Feng, Xuedong Lv, Xiaodong Zhang, Wenjing Xu, Zhengrong Zhang, Guoer Ma, Jian Wang, Tong Zhou, Dahai Zhao, Haohui Fang, Zeyi Liu, Jian-an Huang |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 2 | 40% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 3 | 18% |
| Student > Bachelor | 2 | 12% |
| Student > Master | 2 | 12% |
| Researcher | 2 | 12% |
| Student > Postgraduate | 2 | 12% |
| Other | 0 | 0% |
| Unknown | 6 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 5 | 29% |
| Medicine and Dentistry | 3 | 18% |
| Chemistry | 1 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
| Unknown | 7 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2021.
All research outputs
#15,181,325
of 25,387,668 outputs
Outputs from Frontiers in oncology
#4,555
of 22,433 outputs
Outputs of similar age
#228,930
of 450,788 outputs
Outputs of similar age from Frontiers in oncology
#249
of 938 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,433 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 450,788 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 938 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.